We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Unveils Additional Phase 3 Results for MS Drug Kesimpta
Novartis Unveils Additional Phase 3 Results for MS Drug Kesimpta
Novartis has released new data from a late-stage study showing that its multiple sclerosis (MS) drug Kesimpta (ofatumumab) reduced the risk of disease progression.